FISABIOHOSPITAL UNIVERSITARIO DOCTOR PESET

PNEUMOLOGY

HEAD OF RESEARCH SECTIONEVA MARTÍNEZ MORAGÓNMARTINEZ_EVAMOR@GVA.ES SAN LÁZARO, S/N, 1ª PLANTA / 46017 VALENCIA / SPAIN

FUNDACIÓN PAR A EL FOMENTO DE L A INVEST IGACIÓN SANITARIA Y BIOMÉDIC A DE L A COMUNIDAD VALENCIANA (F ISABIO) / AVENIDA DE C ATALUÑA , 21 / 46020 VALENCIA / SPA IN THE ELABORATION OF THIS DOCUMENT HAS BEEN FUNDED BY THE PROJECT AFI -01/14, IN THE CONTEXT OF THE GRANTS FOR PARTICIPATION IN EUROPEAN COMMISSION RESEARCH PROGRAMMES ON HEALTH GIVEN BY THE CONSELLERIA DE SANITAT UNIVERSAL I SALUT PÚBLICA OF THE GOVERNMENT OF VALENCIA FOR THE 2014-2015 FISCAL PERIOD.

AREAS OF RESEARCH

AREA 1. Determinants of dyspnea in patients with different grades of stable asthma.

AREA 2. Gender differences in Health-Related Quality of life among patients with asthma.

AREA 3. Percepción de mejoría en los pacientes con asma [Perception of improvement in asthma patients].

AREA 4. Percepción de la disnea durante la broncoconstricción aguda en los pacientes con asma [Asthma patients' perception of dyspnea during acute bronchoconstriction].

AREA 5. Prevalencia del síndrome de hiperventilación en pacientes tratados por asma en una consulta de neumología [Prevalence of Hyperventilation Syndrome in Patients Treated for Asthma in a Pulmonology Clinic].

AREA 6. La concordancia entre la percepción de disnea del asmático durante la obstrucción aguda y crónica [Agreement in Asthmatics' Perception of Dyspnea During Acute and Chronic Obstruction].

AREA 7. Near-Fatal Asthma Related to Menstruation.

AREA 8. Evolución temporal de la percepción exagerada de disnea en los pacientes con asma [Evolution Over Time in Over Perceivers of Dyspnea in Asthma].

AREA 9. ¿Influye la experiencia en la percepción de disnea? [Does Experience Influence Perception of Dyspnea?].

AREA 10. ¿Disminuye la incidencia de asma de riesgo vital en España? [Is the Incidence of Near-Fatal Asthma Decreasing in Spain?].

AREA 11. Percepción de la disnea y cumplimiento terapéutico en pacientes con asma [Perception of Dyspnea and Treatment Adherence in Asthmatic Patients].

AREA 12. Impacto de la disnea basal e inducida en la calidad de vida de los pacientes con EPOC [Impact of baseline and induced dyspnoea on the quality of life of patients with COPD].

AREA 13. Coste económico del paciente asmático en España [Economic Cost of Treating the Patient With Asthma in Spain: The AsmaCost Study].

AREA 14. Estudio de marcadores de inflamación en el aire exhalado de pacientes con bronquiectasias no asociadas a fibrosis quística [Inflammation Markers in the Exhaled Air of Patients with Bronchiectasis Unassociated with Cystic Fibrosis].

AREA 15. Creencias sobre la salud y los medicamentos en la población asmática española. Validación de dos instrumentos para su medida [Spanish Asthma Patients’ Beliefs About Health and Medicines: Validation of 2 Questionnaires].

AREA 16. Omalizumab Therapy in Severe Asthma: Experience from the Spanish Registry.

AREA 17. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry.

AREA 18. Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis.

AREA 19. Factors affecting quality of life of asthma patients in Spain: The importance of patient education.

AREA 20. Guidelines for severe uncontrolled asthma.AREA 22. Comparison of different dosages, schedules and routes of administration of furosemide in patients admit ted to the Inpatient Emergency Department with acute heart failure by means of symptom improvement scales through the development of PK/PD models.

To continue our thorough investigation of the nature and management of asthma with the purpose of improving the quality of life of patients.

OBJECTIVES

FOR MORE INFORMATION ON FISABIO’S ACTIVITIES AND SERVICES:

W. FISABIO.SAN.GVA.ES / T. +34 961925700 / M. FISABIO@GVA.ES

FISA

BIO

PNEU

MO

LOG

Y0

2